Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China

被引:32
作者
Duan, Rufei [1 ,2 ]
Qiao, Youlin [1 ,2 ]
Clifford, Gary [3 ]
Zhao, Fanghui [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Int Agcy Res Canc, Lyon, France
来源
CANCER MEDICINE | 2020年 / 9卷 / 01期
基金
中国国家自然科学基金;
关键词
attributable fraction; burden; cancer; China; human papillomavirus; SQUAMOUS-CELL CARCINOMA; POOLED ANALYSIS; HPV VACCINE; PREVENTION; PREVALENCE; WOMEN;
D O I
10.1002/cam4.2697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Human papillomavirus (HPV) attributable cancer burden is currently unknown in China, which is essential to evaluate the potential benefit of existing HPV and to inform cancer control policy. Methods We extracted data of cancer incidence and mortality in 2014 from Chinese Cancer Registry Annual Report, and data of national population from National Bureau of Statistics. HPV-attributable cancer burden was estimated by incorporating cancer rates and population forecasts by sex, cancer site, age and geographical area, and then combined to corresponding population attributable fractions. Results We estimated that there were 110 894 HPV-attributable new cancer cases in China in 2014, including 99 253 cervical cancers, 4449 noncervical cancers in females and 7192 cancers in males. The age-standardized incidence of HPV-attributable cancers in China was 5.69 per 100 000 persons, being slightly higher in rural than urban areas. Specifically, 51.1% of HPV-attributable cervical cancers were diagnosed in women aged 40-54 years, while 75.8% of noncervical cancers were diagnosed at 45-79 years of age. Among males, 53.4% of cancers were diagnosed at 55-74 years of age. Thirty five thousand six hundred and eighty three HPV-attributable cancer deaths were estimated, including 29 683 due to cervical cancer, and 2307 and 3693 due to noncervical cancer in females and males, respectively. Conclusions The cancer burden attributable to HPV in China is substantial. HPV vaccination and cervical screening should be prioritized.
引用
收藏
页码:374 / 384
页数:11
相关论文
共 35 条
  • [1] [Anonymous], J SEX TRANSM DIS
  • [2] Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection
    Beachler, Daniel C.
    Kreimer, Aimee R.
    Schiffman, Mark
    Herrero, Rolando
    Wacholder, Sholom
    Cecilia Rodriguez, Ana
    Lowy, Douglas R.
    Porras, Carolina
    Schiller, John T.
    Quint, Wim
    Jimenez, Silvia
    Safaeian, Mahboobeh
    Struijk, Linda
    Schussler, John
    Hildesheim, Allan
    Gonzalez, Paula
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (01):
  • [3] Cancer incidence in Germany attributable to human papillomavirus in 2013
    Buttmann-Schweiger, Nina
    Delere, Yvonne
    Klug, Stefanie J.
    Kraywinkel, Klaus
    [J]. BMC CANCER, 2017, 17
  • [4] Chen W., 2014, CHIN J CANC RES, V30, P1, DOI [10.21147/j.issn.1000-9604.2018.01.01,2018, DOI 10.21147/J.ISSN.1000-9604.2018.01.01,2018]
  • [5] Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment
    Chen, Wanqing
    Xia, Changfa
    Zheng, Rongshou
    Zhou, Maigeng
    Lin, Chunqing
    Zeng, Hongmei
    Zhang, Siwei
    Wang, Lyon
    Yang, Zhixun
    Sun, Kexin
    Li, He
    Brown, Matthew D.
    Islami, Farhad
    Bray, Freddie
    Jemal, Ahmedin
    He, Jie
    [J]. LANCET GLOBAL HEALTH, 2019, 7 (02): : E257 - E269
  • [6] Worldwide burden of cancer attributable to HPV by site, country and HPV type
    de Martel, Catherine
    Plummer, Martyn
    Vignat, Jerome
    Franceschi, Silvia
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (04) : 664 - 670
  • [7] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
    Dillner, Joakim
    Kjaer, Susanne K.
    Wheeler, Cosette M.
    Sigurdsson, Kristjan
    Iversen, Ole-Erik
    Hernandez-Avila, Mauricio
    Perez, Gonzalo
    Brown, Darron R.
    Koutsky, Laura A.
    Tay, Eng Hseon
    Garcia, Patricia
    Ault, Kevin A.
    Garland, Suzanne M.
    Leodolter, Sepp
    Olsson, Sven-Eric
    Tang, Grace W. K.
    Ferris, Daron G.
    Paavonen, Jorma
    Lehtinen, Matti
    Steben, Marc
    Bosch, F. Xavier
    Joura, Elmar A.
    Majewski, Slawomir
    Munoz, Nubia
    Myers, Evan R.
    Villa, Luisa L.
    Taddeo, Frank J.
    Roberts, Christine
    Tadesse, Amha
    Bryan, Janine T.
    Maansson, Roger
    Lu, Shuang
    Vuocolo, Scott
    Hesley, Teresa M.
    Barr, Eliav
    Haupt, Richard
    [J]. BRITISH MEDICAL JOURNAL, 2010, 341 : 239
  • [8] Forman D., 2014, Cancer incidence in five continents
  • [9] Status of HPV vaccine introduction and barriers to country uptake
    Gallagher, K. E.
    LaMontagne, D. S.
    Watson-Jones, D.
    [J]. VACCINE, 2018, 36 (32) : 4761 - 4767
  • [10] Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015
    Hansen, Bo T.
    Orumaa, Madleen
    Lie, A. Kathrine
    Brennhovd, Bjorn
    Nygard, Mari
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (08) : 1586 - 1593